Related Experiment Video
Updated: Mar 27, 2026
09:30
Author Spotlight: Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies
Published on: March 17, 2023
4.7K
Pharmaceutical Approval Update
P & T : a Peer-Reviewed Journal for Formulary Management
|January 15, 2016
Abstract:
Elotuzumab (Empliciti) and ixazomib (Ninlaro) for some multiple myeloma patients; Fluad (influenza vaccine, adjuvanted) for immunization of persons 65 years of age and older; and osimertinib (Tagrisso) for certain non-small-cell lung cancers.
Insights
New treatments include elotuzumab and ixazomib for multiple myeloma, Fluad for older adults, and osimertinib for non-small-cell lung cancer. These advancements offer targeted therapies for specific patient populations.
Area of Science:
- Oncology
- Immunology
- Vaccinology
Background:
- Multiple myeloma, non-small-cell lung cancer, and influenza pose significant health challenges.
- Existing treatments have limitations, necessitating novel therapeutic approaches.
- Age-related immune changes impact vaccine efficacy in older adults.
Purpose of the Study:
- To review recent advancements in cancer therapies and influenza vaccination.
- To highlight the clinical applications of elotuzumab, ixazomib, and osimertinib.
- To assess the role of Fluad in enhancing immunization for individuals aged 65 and older.
Main Methods:
- Review of clinical trial data and regulatory approvals for elotuzumab, ixazomib, and osimertinib.
- Analysis of studies evaluating Fluad's immunogenicity and efficacy in the elderly.
- Synthesis of information on treatment indications and patient populations.
Main Results:
- Elotuzumab and ixazomib demonstrate efficacy in specific multiple myeloma patient groups.
- Osimertinib shows effectiveness in certain non-small-cell lung cancer cases.
- Fluad provides enhanced immune response for influenza immunization in individuals 65 years and older.
Conclusions:
- These targeted therapies and vaccines represent significant progress in managing specific diseases.
- Personalized medicine approaches are crucial for optimizing treatment outcomes.
- Public health initiatives focusing on vaccination in vulnerable populations remain vital.
Related Concept Videos
01:26FDA Approved Drugs: Changes to Approved Drugs
328
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
328
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
71
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
71
01:25Drug Regulation
3.3K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
3.3K
01:26Drug Administration and Therapy Phases: Overview
1.7K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.7K
01:11Clinical Trials: Overview
5.4K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.4K
01:28Drug Products: Biologics, Biosimilars and Interchangeables
352
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
352